Methocarbamol: a laboratory admitted product contamination, opening a door to explain positive tests

VE TEC S.A. notified Racing Committees that it detected traces of the substance in a batch of its Equisal Electrolitos Pasta, a product used in horses. The finding could provide an explanation for several cases registered in recent weeks, in which trainers maintained they had not administered any medication containing the active ingredient

A letter dated Friday, October 9 could significantly alter the landscape surrounding the numerous positive methocarbamol cases recorded in recent weeks across Argentine racing. The VE TEC S.A. laboratory officially acknowledged detecting contamination with that substance in one of its veterinary products and notified racing committees and track veterinary services across the country.

The news is of immense importance, especially since several of the trainers involved in the cases had assured their horses' owners that they had never administered methocarbamol, nor any medications containing it. Those explanations, received in some quarters with understandable skepticism, now find a potential scientific justification, though it remains to be established whether a concrete connection exists between the positive tests and the contaminated product.

The official notification from VE TEC S.A., addressed directly to authorities at Palermo, San Isidro, La Plata, and other racing bodies, identifies Equisal Electrolitos Pasta, batch 0068, as the product affected by cross-contamination during its packaging process.

The formulation is an oral paste declared to contain potassium chloride, sodium chloride, magnesium chloride, and calcium chloride, along with excipients. That is, an electrolyte supplement whose original composition does not include methocarbamol, an active ingredient used as a muscle relaxant.

According to the laboratory's filing, internal quality control checks and investigations confirmed the presence of traces of that substance, which is foreign to the product's approved formulation.

However, the most compelling piece of evidence appears in the technical report accompanying the letter. Laboratorio Bioeliga S.R.L., through report number 09829 dated October 8, determined a 0.024 percent concentration of methocarbamol in batch 0068. In contrast, tests on batches 0067 and 0066 yielded non-detectable results for the same active ingredient.

The precise analysis pinpoints the single affected batch, offering a crucial document that could prove fundamental for trainers submitting their formal defenses before racing authorities.

In its communication, VE TEC S.A. further contends that the detected traces do not provide any athletic advantage, stimulation, or performance enhancement in horses. That remains, naturally, a statement from the manufacturer itself, which will need to be evaluated by technical racing bodies.

Following the discovery, the company announced the immediate suspension of distribution and recall from the market of all units belonging to the compromised batch, alongside an audit of its manufacturing processes to prevent a recurrence.

Another key aspect is that the laboratory made itself available to racing committees to issue technical certifications and back the formal defenses of trainers and owners who administered the contaminated batch in good faith.

That offer could carry significant weight in open disciplinary proceedings stemming from the positive results.

Over recent weeks, methocarbamol had become a major concern for industry professionals. The outbreak of multiple cases, combined with assertions from trainers who insisted they did not know how the substance entered their horses' systems, had raised troubling questions.

The newly disclosed documentation introduces a possibility that cannot be ignored: that at least some of those adverse findings originated from the use of a contaminated electrolyte supplement rather than the deliberate administration of a banned substance.

Naturally, the laboratory's admission does not imply that every positive test can automatically be attributed to this circumstance. Establishing a link will require verifying which horses received the product, which batch was used, and whether the administration timeline and test levels align with the reported contamination.

It will also be vital to see what approach the Racing Committees adopt regarding this new evidence, particularly in pending cases where a final ruling has not yet been handed down.

The letter bears the signature of VE TEC S.A. Technical Director Horacio M. Arturo, accompanied by the report from the independent testing laboratory that identified the substance.

The ball is now in the court of racing authorities, who must determine the scope of this finding and weigh its potential consequences. If it is proven that any positive tests resulted from a contaminated product, the focus will shift from the mere presence of the substance to the specific circumstances under which it entered the horse's system.